Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Ongoing Initiated Aug 15, 2018 (8 years ago)

Montelukast Sodium Tablets 10 mg

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Labeling: Label Mix-Up - One lot labeled Montelukast Sodium Tablets 10 mg tablets may contain 90 tablets of Losartan Potassium 50 mg.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Montelukast Sodium Tablets 10 mg, 30-count bottle, Rx Only, By: Hetero Hetero Labs Limited, Unit V, Polepally, Jadcherla, Mahaboob Nagar - 509 301, India, Manfuactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854, NDC 31722-726-30

Affected NDC 31722-0726-30

Compare with the code on your package — it is the most precise check available.

Drug: Montelukast

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Montelukast Sodium
NDC 31722-0726
10 mg/1 Tablet, Film Coated
Oral
Camber Pharmaceuticals, Inc. Rx
Recalling firm
Hetero Labs Limited Unit V
NDC code
31722-726-30
Origin
India
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0081-2019 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week.

Other Montelukast recalls

See all
Class II · Moderate risk

Montelukast Sodium Tablets

Presence of Foreign Tablet(s)/Capsule(s): A foreign tablet was found in a bottle of Montelukast Sodium Tablets, USP 10mg, identified as metoprolol 25 mg.

Terminated Particulate / foreign matter Dr. Reddy's Laboratories, Inc. NDC 55111-725-10 D-0086-2024
Class II · Moderate risk

Montelukast Sodium Tablets

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

Ongoing cGMP deviation Preferred Pharmaceuticals, Inc. NDC 68788-9438-3 D-0518-2023

Other recalls by Hetero Labs Limited Unit V

All 2018 recalls
Class II · Moderate risk

Pantoprazole Sodium

Discoloration: Firm received five (5) complaints stating that, "Tablets discolored darker than normal and have lighter-colored spots."

Ongoing Failed specification Hetero Labs Limited (Unit V) NDC 31722-713-10 D-0484-2026
Class II · Moderate risk

Montelukast Sodium Tablets

Discoloration: A complaint was received from a pharmacist for the presence of blue specks on tablets.

Terminated Failed specification Hetero Labs Limited Unit V NDC 31722-726-30 D-1213-2018
Class II · Moderate risk

Camber Pharmaceuticals

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Completed Nitrosamine impurity Hetero Labs Limited Unit V NDC 31722-748-90 D-1116-2018